A Study to Assess the Effects of Durvalumab following Rh-Endostatin combined with reduced-dose CCRT(50 Gy) in Patients with Stage III Unresectable Non-Small Cell Lung Cancer who can not tolerate 60 Gy irradiation.

A Phase II, Single-arm, Multi-centre Study of Durvalumab as Sequential Therapy in Patients with Locally Advanced, Unresectable Non-Small Cell Lung Cancer (Stage III) Who Have Not Progressed Following Rh-Endostatin combined with reduced-dose CCRT(50 Gy) Therapy (Relief)

Inclusion Criteria:

• Age at 18-75 years.
• Documented evidence of NSCLC (locally advanced, unresectable, Stage III)
• Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST)
• Eastern Cooperative Oncology Group performance status score (ECOG PS) of 0 to 1.
• Estimated life expectancy of more than 12 weeks.

Exclusion Criteria:

• Prior exposure to any anti-PD-1 or anti-PD-L1 antibody.
• Active or prior autoimmune disease or history of immunodeficiency.
• Evidence of severe or uncontrolled systemic diseases, including active bleeding diatheses or active infections including hepatitis B, C and HIV.
• Evidence of uncontrolled illness such as symptomatic congestive heart failure, uncontrolled hypertension or unstable angina pectoris.
• Any unresolved toxicity CTCAE >Grade 2 from the prior chemoradiation therapy.
• Active or prior documented inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis).